Exelixis, Invenra partner for multispecific antibodies

Exelixis Inc. (NASDAQ:EXEL) and Invenra Inc. (Madison, Wis.) partnered to identify and develop multispecific antibodies for cancer using Invenra's B-Body platform.

Invenra will be responsible for candidate identification and development up to IND-enabling studies, after which Exelixis will be responsible for development and commercialization. Exelixis will receive an exclusive, worldwide license to one preclinical asset and the companies expect to pursue up to six additional discovery projects under three programs...